To address this problem, “intermittent therapy” (Fig. 7c) has been proposed [39] in which administration is repeated cyclically while monitoring the level of serum prostate-specific antigen (PSA), a noninvasive biomarker quantifying prostate tumor growth. The gene discussed is KLK3; the disease is prostate neoplasm.